BRPI0409379A - combinações de paroxetina e 1-(r)-(3-,5-bis-trifluormetil-fenil)-etil] metilamida do ácido (s)-(4-flúor-2-metil-fenil)-piperazina-1-carboxìlico para tratamento de depressão e/ou ansiedade - Google Patents

combinações de paroxetina e 1-(r)-(3-,5-bis-trifluormetil-fenil)-etil] metilamida do ácido (s)-(4-flúor-2-metil-fenil)-piperazina-1-carboxìlico para tratamento de depressão e/ou ansiedade

Info

Publication number
BRPI0409379A
BRPI0409379A BRPI0409379-8A BRPI0409379A BRPI0409379A BR PI0409379 A BRPI0409379 A BR PI0409379A BR PI0409379 A BRPI0409379 A BR PI0409379A BR PI0409379 A BRPI0409379 A BR PI0409379A
Authority
BR
Brazil
Prior art keywords
phenyl
anxiety
fluoro
depression
bis
Prior art date
Application number
BRPI0409379-8A
Other languages
English (en)
Inventor
Sergio Melotto
Mauro Corsi
Renzo Carletti
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0409379A publication Critical patent/BRPI0409379A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMBINAçõES DE PAROXETINA E 1-(R)-(3,5-BIS-TRIFLUORMETIL-FENIL)-ETIL! METILAMIDA DO áCIDO (S)-(4-FLúOR-2-METIL-PENIL)-PIPERAZINA-1-CARBOXìLICO PARA TRATAMENTO DE DEPRESSãO E/OU ANSIEDADE". A presente invenção diz respeito a combinações terapêuticas compreendendo paroxetina ou sais ou solvatos fisiologicamente aceitáveis desta e ¢1-(R)-(3,5-bis-trifluormetil-fenil)-etil!-metilamida do ácido 2-(S)-(4-flúor-2-metil-fenil)-piperazina-1-carboxílico ou sais ou solvatos fisiologicamente aceitáveis deste, a composições farmacêuticas contendo as ditas combinações e seu uso no tratamento de depressão e/ou ansiedade.
BRPI0409379-8A 2003-04-17 2004-04-16 combinações de paroxetina e 1-(r)-(3-,5-bis-trifluormetil-fenil)-etil] metilamida do ácido (s)-(4-flúor-2-metil-fenil)-piperazina-1-carboxìlico para tratamento de depressão e/ou ansiedade BRPI0409379A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments
PCT/EP2004/004126 WO2004091624A1 (en) 2003-04-17 2004-04-16 Combinations comprising paroxetine and 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety

Publications (1)

Publication Number Publication Date
BRPI0409379A true BRPI0409379A (pt) 2006-04-25

Family

ID=9956996

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0409379-8A BRPI0409379A (pt) 2003-04-17 2004-04-16 combinações de paroxetina e 1-(r)-(3-,5-bis-trifluormetil-fenil)-etil] metilamida do ácido (s)-(4-flúor-2-metil-fenil)-piperazina-1-carboxìlico para tratamento de depressão e/ou ansiedade
BRPI0409377-1A BRPI0409377A (pt) 2003-04-17 2004-04-16 combinações de paroxetina e 1-(r)-(3,5-bis-trifluormetil-fenil)-etil] metilamida do ácido 4-(s)- (4-acentil-piperazin-1-il)-2-(r)-(4-flúor-2-metil-fenil)-pi peridina-1-carboxìlico para tratamento de depressão e/ou ansiedade

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0409377-1A BRPI0409377A (pt) 2003-04-17 2004-04-16 combinações de paroxetina e 1-(r)-(3,5-bis-trifluormetil-fenil)-etil] metilamida do ácido 4-(s)- (4-acentil-piperazin-1-il)-2-(r)-(4-flúor-2-metil-fenil)-pi peridina-1-carboxìlico para tratamento de depressão e/ou ansiedade

Country Status (18)

Country Link
US (4) US20060241124A1 (pt)
EP (4) EP1653956A1 (pt)
JP (4) JP2006523649A (pt)
KR (2) KR20060003875A (pt)
CN (2) CN1809359A (pt)
AU (2) AU2004229179A1 (pt)
BR (2) BRPI0409379A (pt)
CA (2) CA2522313A1 (pt)
CO (1) CO5700753A2 (pt)
GB (1) GB0308968D0 (pt)
IS (2) IS8129A (pt)
MA (2) MA27731A1 (pt)
MX (2) MXPA05011064A (pt)
NO (2) NO20055367L (pt)
PL (2) PL377858A1 (pt)
RU (2) RU2005135649A (pt)
WO (4) WO2004091615A1 (pt)
ZA (2) ZA200508068B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (en) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Stable dosage form of an antidepressant
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
WO2012175434A1 (en) * 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd Piperidine derivatives their preparation and pharmaceutical compositions containing them
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
CA2287397A1 (en) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist and an ssri for treating obesity
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
ES2258485T3 (es) * 1999-12-17 2006-09-01 Schering Corporation Antagonistas selectivos de neuroquinina.
PY0117895A (es) * 2000-07-31 2003-11-03 Pfizer Prod Inc Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
ATE374183T1 (de) * 2001-11-13 2007-10-15 Schering Corp Nk1-antagonisten
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
JP2006523652A (ja) 2006-10-19
KR20060003875A (ko) 2006-01-11
CN1809359A (zh) 2006-07-26
CO5700753A2 (es) 2006-11-30
EP1613325A1 (en) 2006-01-11
WO2004091616A1 (en) 2004-10-28
MA27730A1 (fr) 2006-01-02
MXPA05011063A (es) 2005-12-12
MA27731A1 (fr) 2006-01-02
CA2522313A1 (en) 2004-10-28
NO20055367L (no) 2005-11-14
RU2005135649A (ru) 2006-03-20
US20060241124A1 (en) 2006-10-26
AU2004229181A1 (en) 2004-10-28
CN1809355A (zh) 2006-07-26
KR20060003876A (ko) 2006-01-11
CA2522311A1 (en) 2004-10-28
IS8129A (is) 2005-11-15
IS8128A (is) 2005-11-15
AU2004229179A1 (en) 2004-10-28
JP2006523650A (ja) 2006-10-19
WO2004091615A1 (en) 2004-10-28
US20060241143A1 (en) 2006-10-26
GB0308968D0 (en) 2003-05-28
ZA200508068B (en) 2007-02-28
NO20055368L (no) 2005-11-14
PL377858A1 (pl) 2006-02-20
RU2005135647A (ru) 2006-06-10
EP1615641A1 (en) 2006-01-18
PL377857A1 (pl) 2006-02-20
WO2004091624A1 (en) 2004-10-28
WO2004091617A1 (en) 2004-10-28
EP1615642A1 (en) 2006-01-18
MXPA05011064A (es) 2006-04-18
JP2006523651A (ja) 2006-10-19
US20060217395A1 (en) 2006-09-28
ZA200508067B (en) 2007-02-28
US20060287325A1 (en) 2006-12-21
JP2006523649A (ja) 2006-10-19
EP1653956A1 (en) 2006-05-10
BRPI0409377A (pt) 2006-04-25

Similar Documents

Publication Publication Date Title
BR0309099A (pt) Composições farmacêuticas com base em anticolonérgicos e inibidores da p38 cinase
CY1114118T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
BR0112631A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, pacote, métodos de reduzir a condutáncia de cálcio de um receptor de capsaicina e de tratar um mamìfero e uso de um composto
HUP0500173A2 (hu) Alfa-szulfonamido-acetamid-származékok mint béta-amiloid inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
BRPI0412054A (pt) preparação farmacêutica transdérmica
BRPI0513713A (pt) derivados de piperazina úteis para o tratamento de distúrbios gastrointestinais
DE602005007339D1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
BRPI0409379A (pt) combinações de paroxetina e 1-(r)-(3-,5-bis-trifluormetil-fenil)-etil] metilamida do ácido (s)-(4-flúor-2-metil-fenil)-piperazina-1-carboxìlico para tratamento de depressão e/ou ansiedade
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
BRPI0415826A (pt) derivados de ceto-oxadiazol como inibidores de catepsina
EP1379508A4 (en) N- (ARYL) -2-ARYLETHESULFONAMIDES AND THEIR THERAPEUTIC APPLICATIONS
SE0102147D0 (sv) New methods
UY27416A1 (es) Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana
BRPI0414448A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e um agonista/antagonista de estrogênio
JO2471B1 (en) Antibacterial pharmaceutical compound.
DE60135390D1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
BRPI0409957A (pt) imidazolin-2-ilaminofenil amidas
BR0115281A (pt) Composições de n-(metiletilaminocarbonil)-4-(3-metilfenilamino)-3piri dilsulfonamida e oligossacarìdeos cìclicos
BR0308719A (pt) Composto e sais e solvatos deste, processo para a preparação do mesmo, método de tratamento de um paciente humano ou animal que sofre ou é suscetìvel a uma condição inflamatória, e, composição farmacêutica
MY136976A (en) Novel use of (r)-(-)-2-[5-(4- flourophenyl) -3-pyridylmethylaminomethyl]- chromane and its physiologically acceptable salts
DE50214008D1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]